Eton Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for dehydrated alcohol injection for the treatment of methanol poisoning. The issues raised in the CRL relate primarily to Chemistry Manufacturing and Controls (CMC). The Company believes all issues in the CRL are addressable and will develop a comprehensive action plan to address the FDA's concerns.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 USD | +2.04% | -6.67% | -20.09% |
May. 09 | Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Eton Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.09% | 88.11M | |
+7.74% | 72.81B | |
+12.72% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-16.90% | 2.48B | |
+20.08% | 2.42B | |
-26.13% | 2.32B | |
+19.31% | 2.17B |
- Stock Market
- Equities
- ETON Stock
- News Eton Pharmaceuticals, Inc.
- Eton Pharmaceuticals, Inc. Receives Complete Response Letter for Dehydrated Alcohol Injection